WVE Earnings Date: Feb 25, 2027 (Estimated) — Wave Life Sciences Ltd.
NASDAQ · Healthcare · Biotechnology
Updated
When is WVE's next earnings date?
Wave Life Sciences Ltd. (WVE) is expected to report Q4 2026 earnings on Thursday, February 25, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.34 on revenue of $5.2M.
How did WVE do in its last earnings report?
In its most recent report on Oct 27, 2026 (Q3 2026), Wave Life Sciences Ltd. posted EPS of -$0.30 versus the -$0.33 estimate, a beat of 8.8%. Revenue was $13.2M against a $4.5M estimate. The stock's 1-day post-earnings move was +7.5%.
How much does WVE stock move after earnings?
WVE beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.3% (up or down) in the day after earnings.
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
🤖 AI Earnings Analysis
WVE-006’s planned registrational trial, with biomarker interim analysis potentially supporting accelerated approval in AATD, is the key catalyst. Q3 revenue rose to $13M from $8M, but remains modest and EPS was -$0.30; clinical execution matters more than the beat.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | Q3 2026 | -0.33 | -0.30 | +8.83% | $13.2M | ✅ Beat | +7.48% | — | — |
| 2026-07-30 | Q2 2026 | -0.30 | -0.34 | -13.33% | $2.3M | ❌ Miss | -0.86% | +2.07% | -11.19% |
| 2026-04-28 | Q1 2026 | -0.32 | -0.13 | +59.38% | $38.2M | ✅ Beat | +8.36% | +7.64% | -8.65% |
| 2026-02-26 | Q4 2025 | -0.27 | -0.30 | -11.11% | $17.2M | ❌ Miss | +5.64% | -5.71% | -57.36% |
| 2025-11-10 | Q3 2025 | -0.30 | -0.32 | -6.67% | $7.6M | ❌ Miss | -10.31% | -9.92% | +171.12% |
| 2025-07-30 | Q2 2025 | -0.28 | -0.31 | -10.71% | $8.7M | ❌ Miss | -1.92% | +6.25% | +21.15% |
| 2025-03-04 | Q4 2024 | -0.22 | 0.17 | +177.27% | $83.7M | ✅ Beat | +11.74% | -6.57% | -22.99% |
| 2024-08-08 | Q2 2024 | -0.21 | -0.25 | -19.05% | $19.7M | ❌ Miss | -4.01% | -6.86% | -14.21% |
Showing last 8 quarters.